Back to top
more

ViewRay, Inc. (VRAY)

(Delayed Data from NSDQ)

$7.96 USD

7.96
4,991,682

+1.19 (17.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $7.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Nalak Das headshot

5 Top Momentum Stocks of June Amid Resurgence of Coronavirus

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Top Ranked Momentum Stocks to Buy for June 23rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 23rd

Tandem Diabetes (TNDM) Looks Good: Stock Adds 6.5% in Session

Tandem Diabetes (TNDM) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.

ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of 0.00% and 14.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline

IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.

QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales

QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.

Align Technology (ALGN) Q1 Earnings Miss, Margins Down

Align Technology's (ALGN) Scanner and Services reports COVID-19-led lower sales in North America and APAC region.

Urmimala Biswas headshot

LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down

LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.

Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline

The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.

Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve

Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.

Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand

Masimo (MASI) sees solid growth in key Product segment in Q1.

Ecolab (ECL) Q1 Earnings and Revenues Surpass Estimates

Strength in the Global Industrial and Institutional segments drives Ecolab's (ECL) first-quarter results.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.

Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View

Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.

ViewRay (VRAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics

Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline

Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.

Thermo Fisher (TMO) Q1 Earnings Top, Life Sciences Sales Grow

On coronavirus-led global supply chain disruption, Thermo Fisher (TMO) records a decline in its quarterly Analytical Instruments revenues.

Nalak Das headshot

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance

Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.

ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of -24.00% and -3.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?